|
Thank you very much for your response.
I was thinking that might be the case for some who didn't respond. It IS very helpful just to be able to hear what others went through, how they worked it out or why they wanted to, or what the reasons were that some of the oncs had for saying either yes or no. It is just so puzzling to try to figure out why the rule is that those who are newly diagnosed need traztuzumab more than those who are over a year out, for example, if the risk doesn't even drop significantly until at least 2 years out.
It is especially important to get a sense of how many are wanting the therapy and how many are successfully getting it and how many have insurance that is paying for it.
Thanks again,
AlaskaAngel
|